Abstract
Diabetic nephropathy is the leading cause of end stage renal disease worldwide. The current epidemic of type 2 diabetes (T2D) will lead to further increase in the prevalence of this condition.
In this chapter we review the pathology of diabetic nephropathy in patients with type 1 diabetes (T1D) and T2D. The staging according to presence of albuminuria and chronic kidney disease (CKD) classification is also discussed. We outline the principles of annual screening, investigation and management of patients with diabetes at risk of nephropathy, patients with microalbuminuira and also those with established diabetic nephropathy. The need for preventative therapy including blood glucose and blood pressure control is addressed, and we discuss the importance of ACE inhibitors and angiotensin-2 receptor blockers in the management of these patients. The importance of cardiovascular risk factor management is also highlighted.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Key References
Adler AL, Stevens RJ, Manly SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.
ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.
Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.
Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive T2DM patients. Kidney Int. 2000;57:590–600.
de Boer IH, Sun W, Cleary PA, et al., DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366.
Gaede P, Vedel P, Larsen N, et al. Effect of a multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–593.
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.
Gall MA, Hougaard P, Johnsen KB, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314:783–8.
Holman RR, Paul SK, Bethel MA, et al. 10 years follow up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577.
Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (Clinical research ed). 2004;328(7448):1105.
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419.
Joint Speciality Committee on Renal Medicine of the Royal College of Physicians and the Renal Association, and the Royal College of General Practitioners. Chronic kidney disease in adults: UK guidelines for identification, management and referral. London: Royal College of Physicians; 2006. Last accessed on 9 June 2012.
Krolewski AS, Laffel LMB, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332(19):1251–5.
Microalbuminuria Collaborative Study Group United Kingdom. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ. 1995;311:973–7.
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32 Suppl 2:64–78.
National Kidney Foundation. KDOQI clinical practice guidelines for diabetes and CKD:2012 Update. Available at http://www.kidney.org/professionals/KDOQI/guidelines_diabetesUp/diabetes-ckd-update-2012.pdf. Last accesses 10 June 2013.
Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.
The Microalbuminuria Collaborative Group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med. 1999;16(11):918–25.
The National Institute for Health and Clinical Excellence. Hypertension, clinical management of primary hypertension. NICE CG 127. Available at http://www.bhsoc.org/latest_bhs_management_guidelines. Last accessed 2 Sept 2012.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet. 1998;352:837–53.
UK Renal Registry: 14th annual report: December 2011. Available at www.renalreg.com/reports/2011. Last accessed 2 Sept 2011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Chudleigh, R.A., Kumar, P., Bain, S.C. (2014). Preventing and Managing Renal Disease in Diabetes. In: Chowdhury, T. (eds) Diabetes Management in Clinical Practice. Springer, London. https://doi.org/10.1007/978-1-4471-4869-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4869-2_4
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4868-5
Online ISBN: 978-1-4471-4869-2
eBook Packages: MedicineMedicine (R0)